Duvelisib Effective in Relapsed or Refractory CLL/SLL Patients Who Failed Arzerra, Extension Study Shows
News
Patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who failed prior Arzerra (ofatumumab) treatment achieved robust and durable responses after switching to duvelisib, Verastem Oncology announced. Results from the Phase 3 crossover extension study IPI-145-12 (NCT02049515) ... Read more